Compare AIV & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIV | VCRE |
|---|---|---|
| Founded | 1975 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.7M | 316.4M |
| IPO Year | 1996 | 2026 |
| Metric | AIV | VCRE |
|---|---|---|
| Price | $2.42 | $11.51 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 969.2K | 8.7K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 87.41% | N/A |
| EPS Growth | ★ 616.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $138,486,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $10.47 |
| 52 Week High | $8.03 | $13.15 |
| Indicator | AIV | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 26.67 | 45.84 |
| Support Level | N/A | $10.75 |
| Resistance Level | $2.74 | $13.00 |
| Average True Range (ATR) | 0.05 | 0.63 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 4.55 | 38.81 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.